386 related articles for article (PubMed ID: 34480965)
1. Novel insights into RIPK1 as a promising target for future Alzheimer's disease treatment.
Li S; Qu L; Wang X; Kong L
Pharmacol Ther; 2022 Mar; 231():107979. PubMed ID: 34480965
[TBL] [Abstract][Full Text] [Related]
2. The PKR/P38/RIPK1 Signaling Pathway as a Therapeutic Target in Alzheimer's Disease.
Hugon J; Paquet C
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33808629
[TBL] [Abstract][Full Text] [Related]
3. Receptor-Interacting Protein Kinase 1 (RIPK1) as a Potential Therapeutic Target: An Overview of Its Possible Role in the Pathogenesis of Alzheimer's Disease.
Chan HH; Koh RY; Lim CL; Leong CO
Curr Alzheimer Res; 2019; 16(10):907-918. PubMed ID: 31642777
[TBL] [Abstract][Full Text] [Related]
4. Roles of receptor-interacting protein kinase 1 in SH-SY5Y cells with beta amyloid-induced neurotoxicity.
Chan HH; Leong CO; Lim CL; Koh RY
J Cell Mol Med; 2022 Mar; 26(5):1434-1444. PubMed ID: 35106914
[TBL] [Abstract][Full Text] [Related]
5. Necroptosis and Alzheimer's Disease: Pathogenic Mechanisms and Therapeutic Opportunities.
Zhang R; Song Y; Su X
J Alzheimers Dis; 2023; 94(s1):S367-S386. PubMed ID: 36463451
[TBL] [Abstract][Full Text] [Related]
6. A Recent Update on Pathophysiology and Therapeutic Interventions of Alzheimer's Disease.
Kashif M; Sivaprakasam P; Vijendra P; Waseem M; Pandurangan AK
Curr Pharm Des; 2023; 29(43):3428-3441. PubMed ID: 38038007
[TBL] [Abstract][Full Text] [Related]
7.
Park J; Ha HJ; Chung ES; Baek SH; Cho Y; Kim HK; Han J; Sul JH; Lee J; Kim E; Kim J; Yang YR; Park M; Kim SH; Arumugam TV; Jang H; Seo SW; Suh PG; Jo DG
Sci Adv; 2021 Jan; 7(3):. PubMed ID: 33523877
[No Abstract] [Full Text] [Related]
8. Cognitive enhancing effects of pazopanib in D‑galactose/ovariectomized Alzheimer's rat model: insights into the role of RIPK1/RIPK3/MLKL necroptosis signaling pathway.
Abdelhady R; Younis NS; Ali O; Shehata S; Sayed RH; Nadeem RI
Inflammopharmacology; 2023 Oct; 31(5):2719-2729. PubMed ID: 37458952
[TBL] [Abstract][Full Text] [Related]
9. Synaptic Mitochondria: An Early Target of Amyloid-β and Tau in Alzheimer's Disease.
Torres AK; Jara C; Park-Kang HS; Polanco CM; Tapia D; Alarcón F; de la Peña A; Llanquinao J; Vargas-Mardones G; Indo JA; Inestrosa NC; Tapia-Rojas C
J Alzheimers Dis; 2021; 84(4):1391-1414. PubMed ID: 34719499
[TBL] [Abstract][Full Text] [Related]
10. Molecular and functional characteristics of receptor-interacting protein kinase 1 (RIPK1) and its therapeutic potential in Alzheimer's disease.
Pati S; Singh Gautam A; Dey M; Tiwari A; Kumar Singh R
Drug Discov Today; 2023 Dec; 28(12):103750. PubMed ID: 37633326
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic potentials of plant iridoids in Alzheimer's and Parkinson's diseases: A review.
Dinda B; Dinda M; Kulsi G; Chakraborty A; Dinda S
Eur J Med Chem; 2019 May; 169():185-199. PubMed ID: 30877973
[TBL] [Abstract][Full Text] [Related]
12. Hyperphosphorylated tau mediates neuronal death by inducing necroptosis and inflammation in Alzheimer's disease.
Dong Y; Yu H; Li X; Bian K; Zheng Y; Dai M; Feng X; Sun Y; He Y; Yu B; Zhang H; Wu J; Yu X; Wu H; Kong W
J Neuroinflammation; 2022 Aug; 19(1):205. PubMed ID: 35971179
[TBL] [Abstract][Full Text] [Related]
13. IKKβ Alleviates Neuron Injury in Alzheimer's Disease via Regulating Autophagy and RIPK1-Mediated Necroptosis.
Wang W; Gu X; Cheng Z; Lu X; Xie S; Liu X
Mol Neurobiol; 2022 Apr; 59(4):2407-2423. PubMed ID: 35083662
[TBL] [Abstract][Full Text] [Related]
14. Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer's Disease.
Sun Y; Xu L; Shao H; Quan D; Mo Z; Wang J; Zhang W; Yu J; Zhuang C; Xu K
J Med Chem; 2022 Nov; 65(21):14957-14969. PubMed ID: 36288088
[TBL] [Abstract][Full Text] [Related]
15. Role of tau protein in Alzheimer's disease: The prime pathological player.
Muralidar S; Ambi SV; Sekaran S; Thirumalai D; Palaniappan B
Int J Biol Macromol; 2020 Nov; 163():1599-1617. PubMed ID: 32784025
[TBL] [Abstract][Full Text] [Related]
16. Molecular Insight into the Therapeutic Promise of Flavonoids against Alzheimer's Disease.
Uddin MS; Kabir MT; Niaz K; Jeandet P; Clément C; Mathew B; Rauf A; Rengasamy KRR; Sobarzo-Sánchez E; Ashraf GM; Aleya L
Molecules; 2020 Mar; 25(6):. PubMed ID: 32168835
[TBL] [Abstract][Full Text] [Related]
17. Co-Localization of Glia Maturation Factor with NLRP3 Inflammasome and Autophagosome Markers in Human Alzheimer's Disease Brain.
Ahmed ME; Iyer S; Thangavel R; Kempuraj D; Selvakumar GP; Raikwar SP; Zaheer S; Zaheer A
J Alzheimers Dis; 2017; 60(3):1143-1160. PubMed ID: 28984607
[TBL] [Abstract][Full Text] [Related]
18. Distinct relationships of amyloid-beta and tau deposition to cerebral glucose metabolic networks in Alzheimer's disease.
Sun X; Nie B; Zhao S; Ai L; Chen Q; Zhang T; Pan T; Wang L; Yin X; Zhang W; Shan B; Liu H; Liang S; Wang G
Neurosci Lett; 2020 Jan; 717():134699. PubMed ID: 31874218
[TBL] [Abstract][Full Text] [Related]
19. Artemether Attenuates Aβ25-35-Induced Cognitive Impairments by Downregulating Aβ, BACE1, mTOR and Tau Proteins.
Li HJ; Wang TZ; Hou C; Liu HY; Zhang Y; Xue ZZ; Cai QC; Chen DM; Gao CW; Yang JL; Cong L; Chen Y; Yao Q; Zhu QS; Cao C
Clin Lab; 2021 Oct; 67(10):. PubMed ID: 34655202
[TBL] [Abstract][Full Text] [Related]
20. Alteration of mTOR signaling occurs early in the progression of Alzheimer disease (AD): analysis of brain from subjects with pre-clinical AD, amnestic mild cognitive impairment and late-stage AD.
Tramutola A; Triplett JC; Di Domenico F; Niedowicz DM; Murphy MP; Coccia R; Perluigi M; Butterfield DA
J Neurochem; 2015 Jun; 133(5):739-49. PubMed ID: 25645581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
